Greenwood Capital Associates’s Tandem Diabetes Care TNDM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$348K Buy
23,078
+9,137
+66% +$160K 0.03% 255
2026
Q1
$267K Sell
13,941
-1,409
-9% -$30.6K 0.03% 273
2025
Q4
$337K Buy
+15,350
New +$277K 0.04% 231
2022
Q3
Sell
-5,863
Closed -$347K 227
2022
Q2
$347K Sell
5,863
-2,169
-27% -$178K 0.06% 186
2022
Q1
$934K Buy
8,032
+344
+4% +$40.2K 0.25% 85
2021
Q4
$1.16M Buy
7,688
+37
+0.5% +$4.99K 0.16% 108
2021
Q3
$913K Buy
7,651
+81
+1% +$8.93K 0.14% 118
2021
Q2
$737K Buy
7,570
+87
+1% +$7.76K 0.11% 143
2021
Q1
$660K Buy
7,483
+1,374
+22% +$128K 0.1% 153
2020
Q4
$585K Buy
6,109
+647
+12% +$66.7K 0.1% 151
2020
Q3
$620K Sell
5,462
-662
-11% -$69.6K 0.12% 111
2020
Q2
$606K Sell
6,124
-1,329
-18% -$106K 0.14% 84
2020
Q1
$480K Sell
7,453
-427
-5% -$29.9K 0.14% 78
2019
Q4
$470K Buy
7,880
+2,341
+42% +$144K 0.1% 114
2019
Q3
$327K Buy
+5,539
New +$354K 0.08% 121

Other funds holding TNDM

Greenwood Capital Associates's TNDM Position: Q2 2026 in Review

Greenwood Capital Associates increased its Tandem Diabetes Care (TNDM) stake by 66% in Q2 2026, buying an estimated $160K and bringing the position to 23,078 shares worth $348K. The position accounts for 0.03% of the portfolio, ranked #255.

Greenwood Capital Associates first reported a position in TNDM in Q3 2019 and has held it in 15 quarters since. The position peaked at $1.16M in Q4 2021. 59 funds tracked by Wall St. Rank hold TNDM as of Q2 2026.

  • Greenwood Capital Associates held 23,078 shares of Tandem Diabetes Care worth $348K as of Q2 2026.
  • Greenwood Capital Associates bought 9,137 Tandem Diabetes Care shares in Q2 2026, an estimated $160K.
  • Tandem Diabetes Care made up 0.03% of Greenwood Capital Associates's portfolio in Q2 2026, its #255 holding.
  • Greenwood Capital Associates first reported a position in Tandem Diabetes Care in Q3 2019 and has held it in 15 quarters since.
  • Greenwood Capital Associates's Tandem Diabetes Care position peaked at $1.16M in Q4 2021.
  • 59 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q2 2026.

Based on Greenwood Capital Associates's 13F filing for Q2 2026, filed 28 Jul 2026.